{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037216","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2023-08-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.075957+00:00","generated_at":"2026-06-12T11:15:27.030747+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Acadia Q2 net income $1.1M; DAYBUE launch strong with $23.2M sales; guides Q3 DAYBUE $45-55M","bullets":["Q2 net income of $1.1M ($0.01/share) vs net loss of $34.0M in prior year; total product sales $165.2M.","DAYBUE (trofinetide) first full quarter of sales: $23.2M; expanded licensing deal with Neuren for global rights.","NUPLAZID Q2 sales $142.0M, +5.5% YoY; full year guidance raised to $530-545M.","R&D expenses decreased to $58.8M; SG&A increased to $96.0M due to DAYBUE launch costs.","Appointed Dr. Kevin R. Oliver as SVP, Chief Business Officer; Phase 3 negative symptoms schizophrenia trial enrollment complete, results Q1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037216","json":"https://secwatch.observer/filing/0000950170-23-037216.json","markdown":"https://secwatch.observer/filing/0000950170-23-037216.md","text":"https://secwatch.observer/filing/0000950170-23-037216.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/0000950170-23-037216-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/acad-20230802.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T11:15:27.030747+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b9eb2bb1efec63ddfe5d72f88ccecf200752a1d","claim":"ACADIA PHARMACEUTICALS INC reported the six months ended June 30, 2023 results: revenue $283.7 million, net income a net loss of $41.9 million, or $0.26 per common share, EPS $0.26 per common share.","evidence_excerpt":"Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023, and were $283.7 million for the six months ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/0000950170-23-037216-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended June 30, 2023"},{"label":"Revenue","value":"$283.7 million"},{"label":"Net income","value":"a net loss of $41.9 million, or $0.26 per common share"},{"label":"EPS","value":"$0.26 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"c33bc6ff24eb1ddaa400e8e0152bfd1f280a584e","claim":"ACADIA PHARMACEUTICALS INC reported the second quarter ended June 30, 2023 results: revenue $165.2 million, net income $1.1 million, or $0.01 per common share, EPS $0.01 per common share.","evidence_excerpt":"Total net product sales, comprised of NUPLAZID and DAYBUE were $165.2 million for the three months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1070494/000095017023037216/0000950170-23-037216-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$165.2 million"},{"label":"Net income","value":"$1.1 million, or $0.01 per common share"},{"label":"EPS","value":"$0.01 per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}